BiomX (NYSEAMERICAN:PHGE) Releases Quarterly Earnings Results

BiomX (NYSEAMERICAN:PHGE) issued its earnings results on Wednesday. The company reported ($0.37) earnings per share (EPS) for the quarter, FiscalAI reports.

BiomX Stock Up 0.5%

PHGE stock opened at $0.14 on Thursday. BiomX has a twelve month low of $0.12 and a twelve month high of $12.29. The firm has a market capitalization of $1.61 million, a PE ratio of -0.04 and a beta of 1.35. The stock has a 50-day simple moving average of $0.28 and a two-hundred day simple moving average of $2.20.

Institutional Trading of BiomX

An institutional investor recently bought a new position in BiomX stock. Alyeska Investment Group L.P. bought a new position in BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned approximately 5.99% of BiomX at the end of the most recent reporting period. 40.57% of the stock is currently owned by institutional investors and hedge funds.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.